Cargando…
Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
Phosphodiesterase III inhibitors combine positive inotropic and vasodilator properties. These inhibitors are therefore frequently used to treat low cardiac output and/or severe left heart failure associated with cardiac surgery. Their effects on energy metabolism and visceral organ function are not...
Autores principales: | Simkova, Vladislava, Radermacher, Peter, Barth, Eberhard |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206415/ https://www.ncbi.nlm.nih.gov/pubmed/17572916 http://dx.doi.org/10.1186/cc5924 |
Ejemplares similares
-
Year in review 2006: Critical Care – multiple organ failure, sepsis, and shock
por: Simkova, Vladislava, et al.
Publicado: (2007) -
Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis
por: Ahidjo, Bintou Ahmadou, et al.
Publicado: (2016) -
Central venous oxygen saturation and emergency intubation – another piece in the puzzle?
por: Stahl, Wolfgang, et al.
Publicado: (2009) -
Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid
por: Maki, Takakuni, et al.
Publicado: (2014) -
Year in review 2007: Critical Care – shock
por: Wagner, Florian, et al.
Publicado: (2008)